Table 1.

Patient demographic and clinical characteristics

CharacteristicLevofloxacin Group (n=20)Placebo Group (n=19)P Value
Mean age at transplant (yr)5454.90.78
Women 2 (11)7 (58)0.06
African American3 (15)2 (10.5)0.69
Diabetes mellitus8 (40)9 (47)0.75
Previous transplant1 (0.05)6 (31.6)0.04
Desensitized03 (15.8)0.11
Induction regimen0.11
 Thymoglobulin12 (60)14 (73.7)
 Simulect8 (40)5 (26.3)
Cytomegalovirus disease4 (20)6 (31.6)0.48
Median onset of BK viremia (IQR) (d)118 (64–249)170 (49–344)0.08
Median BK viral load after consent (IQR) (copies/ml)24,075 (6,875–65,981)47,900 (12,500–183,000)0.27
Median peak BK viral load (IQR) (copies/ml)74,875 (31,275–255,325)119,000 (30,200–471,200)0.64
Mean creatinine at BK diagnosis (mg/dl)1.61.80.19
Average duration of treatment (d)29.929.20.51
Leflunomide use4 (20)2 (11)0.66
Prednisone free8 (40)5 (26)0.50
Acute rejection after BK diagnosis1 (5)0 (0)>0.99
  • Unless otherwise noted, values are the number (percentage) of patients. IQR, interquartile range.